Clinical trial · Interventional
Choline PET/CT vs. MeAIB PET/CT in Prostate Cancer
Choline PET/CT vs. MeAIB PET/CT. Better Detection of Bone and Lymph Node Metastases in Prostate Cancer Patients, PROSTAGE III
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease. Current methods for staging of bone metastases are known to be inaccurate. Staging of lymph nodes requires surgery associated with risk of bleeding etc. Prior studies from our department suggest that PET/CT is useful in staging of bone metastases in patients with prostate cancer. The aim of this study is to compare the usefulness of MeAIB PET/CT with current methods for the staging of bone and lymph node metastases in patients with newly diagnosed prostate cancer. Better initial staging will result in better treatment of the individual patient. If we are able to develop a more accurate and non-invasive method of staging patients with undetected metastases on current staging will be spared of the side-effects associated with current treatment and staging- impotence, incontinence, radiation damage, bleeding, infection etc.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Choline PET/CT and MeAIB PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MeAIB PET/CT
- description
- Choline PET/CT and MeAIB PET/CT
- interventionNames
- Device: Choline PET/CT and MeAIB PET/CT
Primary outcomes (1)
- measure
- Metastases to bone (yes/no) Metastases to lymph nodes (yes/no)
- timeFrame
- 1 day (At the time of scan interpretation)
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed, histologically verified PCa and * Written consent and * Planned extended lymph node dissection and * PSA ≥ 20 ng/mL and/or * Gleason score \> 6 and/or * cT-stage ≥ cT2c Exclusion Criteria: * Withdrawal of consent or * Other active malign disease
References
Publications (0)
Data not yet available